2016 U.S. Adult Immunization Schedule

February 11, 2016

2016 U.S. Adult Immunization Schedule

  1. Abigail Zuger, MD

Recommendations include major updates on meningococcal and pneumococcal vaccinations.

  1. Abigail Zuger, MD

Sponsoring Organization: Advisory Committee on Immunization Practices (ACIP)

Target Audience: U.S. primary care clinicians

Background

CDC Adult Immunization Schedule for 2016
Further information about the vaccines listed here is available on the CDC website, along with the extensive footnotes for this table. Reprinted from www.cdc.gov/vaccines/schedules/hcp/adult.html.
CDC Adult Immunization Schedule for 2016

Further information about the vaccines listed here is available on the CDC website, along with the extensive footnotes for this table.

Reprinted from www.cdc.gov/vaccines/schedules/hcp/adult.html.

The ACIP has issued its 2016 recommendations for immunizing adults (age, ≥19). This year's schedule incorporates a few new vaccines and changes in the rules for administering some older ones. Immunization tables and extensive footnotes are available on the CDC website free of charge. We have reprinted the age-specific recommendation table.

What's Changed?

  • Two meningococcal vaccines that offer protection against group B meningococcal disease have been added to the schedule. Group B meningococcal vaccine is recommended for use in high-risk patients (i.e., those exposed in a type B outbreak, those with functional or anatomic asplenia). Either of the group B vaccines can be used, but they are not interchangeable (i.e., patients must receive the same vaccine for all of their doses).

  • A 9-valent human papillomavirus (HPV) vaccine has been added to the schedule, joining bivalent and quadrivalent vaccines as an option for immunizing young adults (age range, 19–26). Any of the vaccines can be used in women; only the 9-valent and quadrivalent vaccines can be used in men.

  • The sequence of 13-valent and 23-valent pneumococcal vaccination is complicated and depends on age and underlying medical conditions. This year, a longer recommended interval between 13-valent and 23-valent vaccination makes the nomogram a little easier to remember: In immunocompetent adults, at least 1 year should separate the two vaccines, no matter which is administered first; in immunocompromised adults, 23-valent vaccination should follow 13-valent vaccination by at least 8 weeks, and 13-valent vaccination should follow 23-valent vaccination by at least 1 year.

Comment

Adult immunizations are increasingly complex, and these guidelines do not help clinicians decide among specific vaccines when several options are available. However, they do continue to offer useful and user-friendly graphics to outline which vaccines are recommended, optional, and contraindicated for adults with a range of chronic medical conditions.

Editor Disclosures at Time of Publication

  • Disclosures for Abigail Zuger, MD at time of publication Editorial boards Clinical Infectious Diseases; Open Forum Infectious Diseases

Citation(s):

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.